Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tracer-agnostic diffusion model-based CT-free attenuation correction for brain PET: Comprehensive evaluation across 14 tracers.

Physics in medicine and biology·2026
Same author

Persistent increased risk of renal replacement therapy following COVID-19: a 2-year follow-up study in Japan using propensity score matching and inverse probability censoring weighting.

BMJ open·2026
Same author

Temporal Association Between Viral Infections and Intussusception: Comparing SARS-CoV-2 and Adenovirus Using Self-Controlled and Case-Control Designs.

The Journal of pediatrics·2026
Same author

Guidelines for the management of Helicobacter pylori infection in Japan: 2024 revised edition.

Journal of gastroenterology·2026
Same author

Impact of COVID-19 on new pharmacotherapy for insomnia: A matched cohort study using the national insurance claims database in Japan.

PloS one·2026
Same author

Impact of COVID‑19 infection on subsequent prescriptions of autonomic dysfunction pharmacotherapy: a nationwide propensity‑score‑matched Cohort study in Japan.

Annals of medicine·2026

Related Experiment Video

Updated: Jun 9, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

COVID-19 as a Potential Trigger for Tuberculosis: Insights From a Large-Scale Japanese Insurance Database Analysis.

Daisuke Miyamori1, Kotaro Ikeda1, Sachi Nagasaka1

  • 1Department of General Internal Medicine Hiroshima University Hospital Hiroshima Japan.

Journal of General and Family Medicine
|June 8, 2026
PubMed
Summary

COVID-19 infection significantly increases the risk of active tuberculosis (TB) treatment initiation. This risk is substantially higher for individuals with a prior history of TB.

Keywords:
COVID‐19National Insurance Databasepropensity score matchingtuberculosis

Related Experiment Videos

Last Updated: Jun 9, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

Area of Science:

  • Infectious Diseases
  • Public Health
  • Epidemiology

Background:

  • The long-term health consequences of COVID-19 are a growing concern.
  • Understanding the potential impact of COVID-19 on tuberculosis (TB) incidence and treatment is crucial for public health strategies.

Purpose of the Study:

  • To investigate the association between COVID-19 infection and the subsequent risk of initiating active tuberculosis treatment.
  • To quantify this risk using a large-scale, nationwide cohort in Japan.

Main Methods:

  • A retrospective cohort study utilized Japan's National Insurance Database (January 2020–December 2022).
  • Propensity score matching (1:1) was employed to create comparable groups of COVID-19 patients and controls.
  • The primary outcome was the initiation of TB treatment, identified by specific diagnosis codes and medication use. Cox proportional hazards models were used for analysis.

Main Results:

  • The study included over 3 million individuals, with a median follow-up of 8 months.
  • COVID-19 infected individuals had a 4.14-fold increased hazard of initiating TB treatment compared to controls.
  • The risk was significantly elevated (HR 14.7) in those with a prior history of TB, and remained high (HR 3.96) even in non-hospitalized COVID-19 patients.

Conclusions:

  • Prior COVID-19 infection is associated with a moderate but significant increase in the risk of active tuberculosis treatment.
  • Individuals with a previous history of TB face a substantially higher risk of TB treatment initiation after COVID-19 infection.